SCHEMBL761716

SCHEMBL761716

CBF

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12207306 0.72
SCHEMBL16230411 0.72
SCHEMBL48190 0.61
SCHEMBL172102 0.61
Methylsulfanylmethane SCHEMBL6558838 0.58
SCHEMBL6897693 0.55
Ammonia Solution, Strong SCHEMBL10611826 0.55
SCHEMBL10039326 0.55
Hydrogen Sulfide SCHEMBL2121945 0.55
Bromide SCHEMBL9080847 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240308936-A1 METHOD FOR PRODUCING ALPHA-OLEFIN OLIGOMER COMPOSITION IDEMITSU KOSAN CO.,LTD. (JP) 2024-09-19 US disclosed
US-12037355-B2 Triterpene saponin analogues ADJUVANCE TECHNOLOGIES, INC. (US) 2024-07-16 US disclosed
EP-4385972-A1 METHOD FOR PRODUCING ALPHA-OLEFIN OLIGOMER COMPOSITION Idemitsu Kosan Co.,Ltd. (JP) 2024-06-19 EP disclosed
CN-117751107-A Organic pyridine-pyrazole compounds and uses thereof 博善人工智能剑桥有限公司 2024-03-22 CN disclosed
US-20240025862-A1 SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2024-01-25 US disclosed
US-20230398224-A1 TARGETED PLASMA PROTEIN DEGRADATION NOVARTIS AG (CH) 2023-12-14 US disclosed
US-11806409-B2 Imaging methods using 18F-radiolabeled biologics BRISTOL-MYERS SQUIBB COMPANY (US) 2023-11-07 US disclosed
US-20230320995-A1 IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES CAPSTAN THERAPEUTICS, INC. (US) 2023-10-12 US disclosed
US-11780836-B2 Process of preparing a PD-1/PD-L1 inhibitor INCYTE CORPORATION (US) 2023-10-10 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20100167554-A1 METHODS FORMING HIGH DIELECTRIC TARGET LAYER SAMSUNG ELECTRONICS CO., LTD. (KR) 2010-07-01 US disclosed
US-20100125069-A1 Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds RIGEL PHARMACEUTICALS INC. (US) 2010-05-20 US disclosed
US-20090320152-A1 MUTATION BREEDING FOR RESISTANCE TO DISEASE AND OTHER USEFUL TRAITS WASHINGTON STATE UNIVERSITY (US) 2009-12-24 US disclosed
EP-2128910-A1 ORGANIC EL DEVICE AND DISPLAY Idemitsu Kosan Co., Ltd. (JP) 2009-12-02 EP disclosed
US-20090280139-A1 Novel Norovirus Particle for Use as an Antiviral or Vaccine NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-11-12 US disclosed
US-20090098438-A1 ION CONDUCTIVE MATERIAL, CONDUCTIVE FILM FOR FUEL CELL, FILM ELECTRODE BONDED BODY AND FUEL CELL RIKEN (JP) 2009-04-16 US disclosed
US-20080200980-A1 PROFILE REDUCTION OF VALVE IMPLANT DIRECT FLOW (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC 2008-08-21 US disclosed
US-20070287800-A1 Lubricious Compounds For Biomedical Applications Using Hydrophilic Polymers FOSTER CORPORATION (US) 2007-12-13 US disclosed
US-20070134328-A1 OXYMORPHONE CONTROLLED RELEASE FORMULATIONS ENDO PHARMACEUTICALS, INC. (US) 2007-06-14 US disclosed
US-20070088088-A1 Method for preventing or treating metabolic syndrome KISSEI PHARMACEUTICAL CO., LTD. 2007-04-19 US disclosed